-
15-valent pneumonia vaccine! EU approval of Vaxneuvance: for people aged 6 weeks - under 18 years old!
Time of Update: 2022-10-31
October 25, 2022 /BioValleyBIOON/ --Merck & Co has announced that the European Commission (EC) has approved Vaxneuvance (15-valent pneumococcal conjugate vaccine [PCV], V114) to expand its indication for active immunization of infants, children and adolescents aged 6 weeks to under 18 years of age to prevent invasive diseases, pneumonia and acute otitis media caused by 15 serotypes of Streptococcus pneumoniae 。 In the EU, Vaxneuvance has previously been approved for use in adults aged 18 and over.
-
Concerned about cervical cancer Is it safe for Chinese women aged 26 years and older to receive
Time of Update: 2022-10-01
The results of the Key Efficacy Study (HPV-039, NCT00779766) proved that within 6 years of the first vaccination, the three-dose AS04-HPV-16/18 vaccine was still effective for Chinese women aged 18 to 25 who had been vaccinated but had persistent infection with HPV-16/18 virus for 6 months and had grade 1 or higher cervical intraepithelial neoplasia (CIN1+), so it was approved for domestic introduction.
-
Xinkol is highly effective in preventing HPV-16/18-related lesions and persistent infections in women aged 18-45 years
Time of Update: 2022-09-08
This publication is a 66-month follow-up analysis of Cecolin Phase III clinical trials to assess their effectiveness, safety and immunogenicity in the prevention of HPV16/18-related lesions and persistent infections in healthy Chinese women aged 18-45 years.
-
Should people under the age of 18 be vaccinated against the new crown?
Time of Update: 2021-11-05
Relevant parties are requested to check separately when adopting or using this as a basis for decision-making .
-
vaccine in healthy people aged 18 years or older: safe and reliable
Time of Update: 2021-08-08
The study conducted two single-center, randomized, double-blind, placebo-controlled phase 1 and phase 2 trials to evaluate the safety and tolerance of recombinant COVID-19 vaccine (Sf9 cells) in healthy Chinese people aged 18 years or older.
-
Merck's 15-valent pneumonia vaccine V114 is approved by the U.S. FDA for use in adults ≥18 years of age
Time of Update: 2021-08-03
S. Food and Drug Administration (FDA) has approved Vaxneuvance (15-valent pneumococcal conjugate vaccine, V114) for use in adults aged 18 and over to prevent 15 types of Streptococcus pneumoniae serotypes.
-
US FDA approves Pfizer Prevnar 20: for adults ≥18 years of age
Time of Update: 2021-06-16
S. Food and Drug Administration (FDA) has approved Prevnar 20 (pneumococcal 20-valent conjugate vaccine, 20vPnC) for use in adults aged 18 and over to prevent the vaccine caused by the serotype of Streptococcus pneumoniae Of aggressive diseases and pneumonia .
-
[New research] Between the ages of 13 and 18, drinking a cup of about 236ml of sugar-sweetened
Time of Update: 2021-05-22
Recently, researchers published a paper entitled "Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women" in the "Gut" magazine (Figure 1).
-
China CDC responds to when people under 18 years of age can get the new crown vaccine
Time of Update: 2021-04-13
Wang Huaqing, chief expert of the China Centers for Disease Control and Prevention's immunization program, responded on the 28th and said that from the perspective of the country as a whole, the vaccination strategy will be continuously improved based on the needs of epidemic prevention and control and clinical data, including the newborn population.
-
Bronger Ingehandabyl esters prevent and control of children aged 0-18 years VTE was positively evaluated by CHMP
Time of Update: 2021-01-16
The positive evaluation is based on a dedicated pediatric clinical program for the Dabiga group, including the DIVERSITY study, which complements the clinical evidence profile of safety and efficacy in adults established by the Dabiga group, and recently announced that the European Medicines Agency's Human Medicines Committee (CHMP) has adopted a positive evaluation of the treatment of venous thrombosis events (VTE) and prevention of VTE resuscemia in children under 18 years of age.
-
by the European Union: treatment of patients with moderate to severe plaque psoriasis patients aged 6-18 years!
Time of Update: 2020-08-06
According to the Children's Skin Disease Quality of Life Index (CDLQI) 0/1 response, half of the children with moderate to severe plaque psoriasis were completely relieved by the symptom burden of psoriasis by 12 weeks.
-
: treatment of patients with moderate to severe plaque psoriasis patients aged 6-18 years!
Time of Update: 2020-07-19
, 27 June 2020 / BIOON/ Novartis announced that the European Medicines Agency (EMA) Human Pharmaceutical Products Committee (CHMP) has issued a positive review recommending approval for anti-infl
-
of concurrent urinary tract infections in children aged 3 months to 18 years
Time of Update: 2020-06-24
Cephalosporine-Avisin is effective and well tolerated in adults with complex urinary tract infections (cUTI), but has not been evaluated in children with cUTI this single-blind, multi-center, ac
-
CHMP approves Veyvondi for adult patients with vascular haemophilia aged 18 and over
Time of Update: 2020-06-11
Recently, the Pharmaceutical (Corporate (Announced, European Medicines (EMA) Pharmaceutical (CHMP) has issued a positive opinion recommending the approval of Veyvondi (vo nicog alfa, recombin
-
FDA approves Xerava to treat complex intracranal infections in adults over 18 years of age
Time of Update: 2020-06-11
recently, the U.S Food and Drug ( FDA ()) has approved Xerava to treat complex intracranic infections (intried intra-abdominals, cIAIs) in adults over the age of 18 Eravacyclin Eravacycline is